A
Alpheus Medical
A privately held company based in Oakdale, Minnesota, developing a novel sonodynamic therapy platform targeting solid body cancers
About Alpheus Medical
Alpheus Medical, Inc. is a privately held, clinical-stage oncology company founded in 2020 by Dr. Vijay Agarwal. Dr. Agarwal, a practicing brain tumor surgeon with a background in electrical and biomedical engineering, established the firm to address the significant challenges in treating aggressive solid tumors. His career, including a neurosurgery residency at Duke University and over two decades in the medical device and biotechnology industry, has been dedicated to improving outcomes for brain cancer patients.
The company is developing a non-invasive sonodynamic therapy (SDT) platform to treat solid body cancers, with a primary focus on glioblastoma (GBM), the most aggressive form of primary brain cancer. Alpheus Medical's business model centers on the development and commercialization of its proprietary drug-device combination therapy. The treatment is designed for an outpatient setting, which could significantly improve the quality of life for patients. The company's target market consists of patients with difficult-to-treat solid tumors, particularly those with newly diagnosed or recurrent glioblastoma.
Alpheus Medical's core product is a sonodynamic therapy that combines an orally administered, FDA-approved drug called 5-aminolevulinic acid (5-ALA) with the company's proprietary low-intensity diffuse ultrasound (LIDU™) device. The process begins with the patient ingesting 5-ALA, which selectively accumulates in cancer cells. Subsequently, the non-invasive device applies ultrasound to the entire brain hemisphere, which activates the drug. This activation causes the release of reactive oxygen species, a form of oxygen that destroys the targeted cancer cells while sparing healthy tissue. A key benefit of this approach is its ability to treat the entire hemisphere without requiring imaging or sedation during the procedure.
The company has achieved significant milestones, including receiving both Orphan Drug and Fast Track designations from the U.S. FDA in July 2022 for its treatment of recurrent glioblastoma. Alpheus has progressed through multiple funding rounds, securing a $16 million Series A in November 2021 and an oversubscribed $52 million Series B in May 2025. These funds are supporting a Phase 2B randomized controlled trial for newly diagnosed GBM. Early clinical trials have shown promising results, with data indicating a doubling of median overall survival and a threefold improvement in progression-free survival for patients with recurrent high-grade gliomas compared to historical averages. The company collaborates with leading neuro-oncology experts and is backed by prominent investors, including the American Cancer Society and the National Brain Tumor Society.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2025 | $52M | $208M | Sontag foundation · Brain Tumor Investment Fund · Samsara BioCapital · OrbiMed | ↗ |
| SERIES AOther financing | Nov 2022 | $14M | $80M | OrbiMed · Action Potential Venture Capital · SV Health Investors · BrightEdge | ↗ |
Growth signals
Latest recorded traffic for Alpheus Medical is 1.5K monthly website visits, down 16.7% over the last three months. Alpheus Medical's team grew 22.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Alpheus Medical in the Chanhassen ecosystem
The Alpheus Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
OrbiMed
Action Potential Venture Capital
BrightEdge
SV Health Investors
Brain Tumor Society
Samsara BioCapital
HealthQuest Capital
Sontag foundation
Brain Tumor Investment Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alpheus Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alpheus Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








